Aa
Assembly Biosciences to Present Data on HBV Core Protein Allosteric Modifiers
http://www.econotimes.com/Assembly-Biosciences-to-Present-Data-on-New-Series-of-HBV-Core-Protein-Allosteric-Modifiers-at-The-International-Liver-Congress%E2%84%A2-2016-186483
Assembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress™ 2016
Wednesday, March 30, 2016 11:30 AM UTC
BARCELONA, Spain and NEW YORK, March 30, 2016 -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for addressing the gut microbiome and new approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection, today announced that it will present preclinical data on its unique series of HBV Core Protein Allosteric Modifiers (CpAMs) at the upcoming International Liver CongressTM 2016 in Barcelona, Spain.
The presentation, titled Abstract FRI-104: Preclinical Characterization of Potent Core Protein Allosteric Modifiers for the Treatment of Chronic Hepatitis B, will be presented on Friday, April 15, 2016 during a Hepatitis Poster Session starting at 8:00 am local time. Click here to locate and view the presentation Abstract, which is also posted on the Investor page of the company’s website.
Assembly’s Core Protein Allosteric Modifiers are a novel class of direct acting antivirals for the treatment of chronic HBV. Assembly’s EASL presentation characterizes a novel series of potent, pan-genotypic CpAMs that are designed to be used alone or in combination with current standard of care HBV therapies to achieve higher rates of cure. Representative molecules in the series demonstrated potent HBV antiviral activity, a positive in vitro safety profile and promising pharmacokinetic properties. The authors conclude that the potency, favorable preclinical activity and positive preclinical safety profiles demonstrated by these molecules support selection of a CpAM from the series to advance into Phase 1 clinical studies.
Assembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress™ 2016
Wednesday, March 30, 2016 11:30 AM UTC
BARCELONA, Spain and NEW YORK, March 30, 2016 -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for addressing the gut microbiome and new approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection, today announced that it will present preclinical data on its unique series of HBV Core Protein Allosteric Modifiers (CpAMs) at the upcoming International Liver CongressTM 2016 in Barcelona, Spain.
The presentation, titled Abstract FRI-104: Preclinical Characterization of Potent Core Protein Allosteric Modifiers for the Treatment of Chronic Hepatitis B, will be presented on Friday, April 15, 2016 during a Hepatitis Poster Session starting at 8:00 am local time. Click here to locate and view the presentation Abstract, which is also posted on the Investor page of the company’s website.
Assembly’s Core Protein Allosteric Modifiers are a novel class of direct acting antivirals for the treatment of chronic HBV. Assembly’s EASL presentation characterizes a novel series of potent, pan-genotypic CpAMs that are designed to be used alone or in combination with current standard of care HBV therapies to achieve higher rates of cure. Representative molecules in the series demonstrated potent HBV antiviral activity, a positive in vitro safety profile and promising pharmacokinetic properties. The authors conclude that the potency, favorable preclinical activity and positive preclinical safety profiles demonstrated by these molecules support selection of a CpAM from the series to advance into Phase 1 clinical studies.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
